| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 30 May 2024 | 13 May 2024 |
| PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 inter alia to consider and approve the Audited Financial Results for the Quarter and Financial Year ended March 31 2024. With reference to our earlier announcement dated March 27 2024 intimating the Closure of Trading Window pursuant to the Companys Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time the trading window of the Company shall remain closed for all Designated Persons of the Company till June 01 2024. We would like to inform that pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 , the Board of Directors of the Company has, at its meeting held today, i.e. May 30, 2024, inter-alia, considered and approved the Standalone and Consolidated Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2024. The same was also reviewed by the Audit Committee in its meeting held on May 29, 2024. Read less.. (As Per BSE Announcement Dated on 30.05.2024) The Board in its meeting held on 30.05.2024 approved the re-designation of Mr. Ankesh Jain from Whole-time director designated as Director Sales & Marketing to Whole-time Director of the Company for the remaining tenure of his Term i.e. from 01.06.2024 to 31.03.2025. The Board of Directors of the Companys wholly owned subsidiary company, Panacea Biotec Pharma Ltd. has also re-designated Mr. Ankesh Jain who is currently acting as its non-executive Director, to the position of Whole-time Director w.e.f. 01.06.2024. Mr. Ankesh Jain is not debarred from holding the office of Whole-time director in the Company as well as Panacea Biotec Pharma Ltd, by virtue of SEBI order or any other such authority (As Per BSE Announcement dated on 31.05.2024) | ||
| Board Meeting | 13 Feb 2024 | 30 Jan 2024 |
| PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and nine months ended December 31 2023. The trading window of the Company shall remain closed for all Designated Persons of the Company till February 15 2024 and the same will re-open from February 16 2024 1. Standalone and Consolidated Unaudited Financial Results (Provisional) along with Limited Review Report for the quarter and nine months ended December 31, 2023 2. Re-appointment of Mr. Bhupinder Singh as a Non-Executive Independent Director 3. Appointment of Mrs. Ambika Sharma as an additional director in the capacity of Non-Executive Independent Director (As per BSE Announcement Dated on 13/02/2024) | ||
| Board Meeting | 10 Nov 2023 | 23 Oct 2023 |
| PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and half year ended September 30 2023. The trading window of the Company shall remain closed for all Designated Persons of the Company till November 12 2023 We would like to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. November 10, 2023, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and half year ended September 30, 2023. The same were also reviewed by the Audit Committee in its meeting held on November 09, 2023. A copy of the said statement of financial results along with the Limited Review Report is enclosed herewith. The meeting of the Board of Directors commenced at 11:30 A.M. and concluded at 01:25 P.M. (As Per BSE Announcement Dated on 10/11/2023) | ||
| Board Meeting | 12 Aug 2023 | 29 Jul 2023 |
| PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2023 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter ended June 30 2023. PANACEA BIOTEC LIMITED has informed BSE about Board Meeting to be held on 12 Aug 2023 to consider financial statements for the period ended June 2023. Financial results / Other business. The Board considered and approved following matters:- (i) Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company for quarter ended 30.06.2023; (ii) Revision in policy for determination of materiality of events and information and code of Conduct (iii) Date, time and venue of 39th Annual General Meeting - Friday, 29.09.2023 at 11:30 A.M (iv)Dates of Book Closure - 22.09.2023 to 29.09.2023 (As per BSE Announcement Dated on 12/08/2023) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
